ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Open access · hybridAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 52 citations in OpenAlex.
- Comprehensive molecular characterization identifies therapeutic vulnerabilities in ovarian clear cell carcinoma.Genome medicine · 2026Article
- The metabolic environment within solid tumors drives a complex crosstalk between macrophages and NK cells.Frontiers in immunology · 2026Review
- Establishment and characterization of ovarian clear cell carcinoma patient-derived xenografts.Scientific reports · 2025Article
- Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma.Cancer chemotherapy and pharmacology · 2025Article
- Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.Journal of translational medicine · 2024Article
- From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.Journal of ovarian research · 2024Review
- Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.Annals of medicine · 2023Article
- Genomic landscapes of ovarian clear cell carcinoma from latin countries reveal aberrations linked to survival and progression.BMC cancer · 2023Article
- Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.Journal of ovarian research · 2023Article
- Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics.Frontiers in genetics · 2023Review
- CRISPR/Cas9 Screening for Identification of Genes Required for the Growth of Ovarian Clear Cell Carcinoma Cells.Current issues in molecular biology · 2022Article
- Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Everolimus combined with 5-aza-2-deoxycytidine generated potent anti-tumor effects on ovarian clear cell cancer stem-like/spheroid cells by inhibiting the COL6A3-AKT-mTOR pathway.American journal of cancer research · 2022Article
- AMPK-mTOR Signaling and Cellular Adaptations in Hypoxia.International journal of molecular sciences · 2021Review
- Review
- Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors.Cancers · 2021Article
- Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Article
- Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma.Frontiers in oncology · 2021Review
- Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review.Annals of translational medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 9 institutions in 8 countries.
Joseph J CaumannsDepartment of Gynecologic Oncology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Katrien BernsDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
G Bea A WismanDepartment of Gynecologic Oncology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Rudolf S N FehrmannDepartment of Medical Oncology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Tushar TomarDepartment of Gynecologic Oncology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Harry KlipDepartment of Gynecologic Oncology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Gert J MeersmaDepartment of Gynecologic Oncology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
E Marielle HijmansDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Annemiek M C GennissenDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Evelien W DuikerDepartment of Pathology and Medical Biology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Desiree WeeningDepartment of Genetics, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Hiroaki ItamochiDepartment of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Iwate, Japan.
Roelof J C KluinDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Anna K L ReynersDepartment of Medical Oncology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Michael J BirrerCenter for Cancer Research, The Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Helga B SalvesenDepartment of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway.
Ignace VergoteDepartment of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Els van NieuwenhuysenDepartment of Gynaecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
James BrentonCancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge, United Kingdom.
E Ioana BraicuDepartment of Gynecology, Charité Medical University, Berlin, Germany.
Jolanta KupryjanczykDepartment of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Beata SpiewankiewiczDepartment of Gynecologic Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Lorenza MittempergherDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
René BernardsDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ate G J van der ZeeDepartment of Gynecologic Oncology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Steven de JongDepartment of Medical Oncology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. s.de.jong@umcg.nl.ORCID 0000-0001-5831-6997
University Medical Center Groningen · NLOncode Institute · NLThe Maria Sklodowska-Curie National Research Institute of Oncology · PLVIB-KU Leuven Center for Cancer Biology · BECancer Research UK Cambridge Center · GBCenter for Cancer Research · USCharité - Universitätsmedizin Berlin · DEHaukeland University Hospital · NOIwate Medical University · JP
Funding
Cancer Research UK A15601
Abstract
PubMed holds no abstract for this paper.
Indexed as
Adenocarcinoma, Clear CellAnimalsCell Line, TumorCell ProliferationClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticHeterograftsHumansMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MiceMorpholinesMutationNuclear Proteins(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanolARID1A protein, humanClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MorpholinesNuclear ProteinsPIK3CA protein, humanTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.